| Primary |
| Product Used For Unknown Indication |
63.7% |
| Pain |
18.2% |
| Back Pain |
3.1% |
| Cancer Pain |
3.1% |
| Depression |
1.3% |
| Hypertension |
1.1% |
| Pain Management |
0.9% |
| Insomnia |
0.9% |
| Osteoarthritis |
0.9% |
| Arthralgia |
0.8% |
| Breakthrough Pain |
0.8% |
| Analgesic Therapy |
0.6% |
| Breast Cancer Metastatic |
0.6% |
| Hepatic Cancer |
0.6% |
| Intervertebral Disc Protrusion |
0.6% |
| Neuralgia |
0.6% |
| Plasma Cell Myeloma |
0.6% |
| Sciatica |
0.5% |
| Spinal Pain |
0.5% |
| Anxiety |
0.5% |
|
| Wrong Technique In Drug Usage Process |
39.5% |
| Off Label Use |
15.0% |
| Product Quality Issue |
10.4% |
| Drug Prescribing Error |
7.9% |
| Inappropriate Schedule Of Drug Administration |
5.6% |
| Vomiting |
4.8% |
| Somnolence |
4.6% |
| Overdose |
1.5% |
| Medication Error |
1.2% |
| Pain |
1.2% |
| Toxicity To Various Agents |
1.0% |
| Withdrawal Syndrome |
1.0% |
| Incorrect Drug Administration Duration |
0.8% |
| Intentional Drug Misuse |
0.8% |
| Intestinal Obstruction |
0.8% |
| Product Adhesion Issue |
0.8% |
| Treatment Noncompliance |
0.8% |
| Urinary Retention |
0.8% |
| Disease Progression |
0.6% |
| Drug Administration Error |
0.6% |
|
| Secondary |
| Product Used For Unknown Indication |
41.2% |
| Pain |
19.9% |
| Back Pain |
7.8% |
| Cancer Pain |
5.8% |
| Intervertebral Disc Protrusion |
5.2% |
| Hypertension |
2.5% |
| Electrolyte Substitution Therapy |
1.7% |
| Fibromyalgia |
1.6% |
| Arthralgia |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Sciatica |
1.4% |
| Abdominal Pain |
1.2% |
| Osteoporosis |
1.2% |
| Thrombosis Prophylaxis |
1.2% |
| Hypothyroidism |
1.1% |
| Bone Pain |
1.0% |
| Breast Cancer |
1.0% |
| Osteoarthritis |
1.0% |
| Squamous Cell Carcinoma |
0.9% |
| Stupor |
0.9% |
|
| Wrong Technique In Drug Usage Process |
39.3% |
| Vomiting |
8.9% |
| Off Label Use |
6.1% |
| Somnolence |
5.6% |
| Withdrawal Syndrome |
5.6% |
| Inappropriate Schedule Of Drug Administration |
5.1% |
| Drug Prescribing Error |
3.7% |
| Product Quality Issue |
3.3% |
| Treatment Noncompliance |
2.8% |
| Pain |
2.3% |
| Death |
1.9% |
| Hepatitis |
1.9% |
| Hepatitis Acute |
1.9% |
| Malaise |
1.9% |
| Monocytopenia |
1.9% |
| Urinary Retention |
1.9% |
| Weight Increased |
1.9% |
| Overdose |
1.4% |
| Psoriasis |
1.4% |
| Renal Failure |
1.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
34.0% |
| Pain |
11.4% |
| Plasma Cell Myeloma |
7.1% |
| Hypertension |
7.0% |
| Prophylaxis |
5.8% |
| Tumour Pain |
3.8% |
| Depression |
3.7% |
| Breast Cancer Metastatic |
3.1% |
| Bone Pain |
2.7% |
| Metastases To Bone |
2.4% |
| Back Pain |
2.3% |
| Drug Use For Unknown Indication |
2.3% |
| Thrombosis Prophylaxis |
2.2% |
| Osteoporosis |
2.0% |
| Atrial Fibrillation |
1.8% |
| Prostate Cancer |
1.8% |
| Constipation |
1.7% |
| Non-small Cell Lung Cancer |
1.7% |
| Rheumatoid Arthritis |
1.7% |
| Anticoagulant Therapy |
1.6% |
|
| Vomiting |
15.0% |
| Thrombocytopenia |
12.4% |
| Weight Decreased |
8.8% |
| Osteonecrosis Of Jaw |
6.2% |
| Renal Failure Acute |
6.2% |
| Septic Shock |
6.2% |
| Off Label Use |
4.4% |
| Pyrexia |
4.4% |
| Death |
3.5% |
| General Physical Health Deterioration |
3.5% |
| Lung Disorder |
3.5% |
| Rash |
3.5% |
| Rhabdomyolysis |
3.5% |
| Disease Progression |
2.7% |
| Febrile Bone Marrow Aplasia |
2.7% |
| Gastrointestinal Haemorrhage |
2.7% |
| Malaise |
2.7% |
| Neutropenia |
2.7% |
| Osteonecrosis |
2.7% |
| Pain |
2.7% |
|
| Interacting |
| Product Used For Unknown Indication |
56.0% |
| Pain |
12.0% |
| Ascites |
8.0% |
| Plasma Cell Myeloma |
8.0% |
| Arterial Stenosis |
4.0% |
| Chronic Hepatitis |
4.0% |
| Hyperlipidaemia |
4.0% |
| Lymphoma |
4.0% |
|
| Drug Interaction |
40.0% |
| Cardio-respiratory Arrest |
20.0% |
| Renal Impairment |
20.0% |
| Vomiting Projectile |
20.0% |
|
